









Markets
/
Stocks
/
nasdaq-tcrx
/

TScan Therapeutics Inc

TCRX

1.790USD

+0.070+4.07%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

101.58MMarket Cap

LossP/E TTM



TScan Therapeutics Inc

1.790

+0.070+4.07%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

66 / 506

Overall Ranking

158 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

8.500

Target Price

+394.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.82M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 92.54.

Fairly Valued

The company’s latest PE is -1.64, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 48.33M shares, decreasing 1.93% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.15M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.36.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.37, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 3.08M, representing a year-over-year increase of 473.88%, while its net profit experienced a year-over-year increase of 16.71%.

Score

Industry at a Glance

Previous score

7.37

Change



Financials

8.27

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.06

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.55

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.57, which is -29.88% below the recent high of -1.10 and -164.05% above the recent low of -4.15.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 66/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for TScan Therapeutics Inc is 9.50, with a high of 12.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

8.500

Target Price

+394.19%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

TScan Therapeutics Inc

TCRX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.26, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.92 and the support level at 1.56, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.26

Change

0.28

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.033

Neutral

RSI(14)

50.986

Neutral

STOCH(KDJ)(9,3,3)

41.075

Buy

ATR(14)

0.114

High Vlolatility

CCI(14)

-33.855

Neutral

Williams %R

47.222

Neutral

TRIX(12,20)

-0.067

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.704

Buy

MA10

1.769

Buy

MA20

1.813

Sell

MA50

1.790

Sell

MA100

1.645

Buy

MA200

1.962

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 92.38%, representing a quarter-over-quarter increase of 3.85%. The largest institutional shareholder is The Vanguard, holding a total of 2.15M shares, representing 4.10% of shares outstanding, with 10.06% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Lynx1 Capital Advisors LLC

7.95M

+48.32%

BVF Partners L.P.

4.89M

+63.56%

K2 HealthVentures LLC

3.60M

+414.67%

Baker Bros. Advisors LP

2.78M

The Vanguard Group, Inc.

Star Investors

2.36M

-1.08%

Propel Bio Management, LLC

2.09M

Pitango Venture Capital

2.08M

BlackRock Financial Management, Inc.

1.84M

-1.14%

Bessemer Venture Partners

1.25M

Alphabet, Inc.

1.08M

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.01, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.98. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.